Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology
The DOI matches its Crossref record; 299 of the 300 references it cites were found in a registry or an index.
Abstract
Bile acids (BAs) can regulate their own metabolism and transport as well as other key aspects of metabolic homeostasis via dedicated (nuclear and G protein-coupled) receptors. Disrupted BA transport and homeostasis results in the development of cholestatic disorders and contributes to a wide range of liver diseases, including nonalcoholic fatty liver disease and hepatocellular and cholangiocellular carcinoma. Furthermore, impaired BA homeostasis can also affect the intestine, contributing to the pathogenesis of irritable bowel syndrome, inflammatory bowel disease, and colorectal and oesophageal cancer. Here, we provide a summary of the role of BAs and their disrupted homeostasis in the development of gastrointestinal and hepatic disorders and present novel insights on how targeting BA pathways might contribute to novel treatment strategies for these disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additional microbial metabolites, such as conjugated bile acids, can activate the farnesoid X receptor, suppressing hepatic stellate cell activation and fibrogenic signaling, thereby ameliorating liver fibrosis105,106.”
From Emerging strategies in senotherapeutics: from broad-spectrum senolysis to precision reprogramming (2026) · cites this paper as [105]
In the citing paper
“Moreover, BAs have the potential to modulate the gut–brain axis by maintaining intestinal homeostasis, as TGR5 and FXR signaling are pivotal regulators of intestinal immune response and barrier function.365,376”
From Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases (2024) · cites this paper as [376]
In the citing paper
“Peroxisome proliferator-activated receptors (PPARs), liver X receptors (LXRs), FXR and THR (particularly THR-β) are the most extensively studied receptors that are targets for therapy.20–22”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [20]
Citations
Cites
Items 201–299 of 299
Dent, P., Fang, Y., Gupta, S., Studer, E., Mitchell, C., Spiegel, S., & Hylemon, P. B. (2005) · Hepatology · doi:10.1002/hep.20942 · Cited by 125
Boyer, J. L. (2013) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2013.tb00519.x · Cited by 124
Menges, M. (2001) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)02308-x · Cited by 123
Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease
Nijmeijer, R. M., Gadaleta, R. M., van Mil, S. W. C., van Bodegraven, A. A., Crusius, J. B. A., Dijkstra, G., Hommes, D. W., de Jong, D. J., Stokkers, P. C. F., Verspaget, H. W., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023745 · Cited by 119
Nuclear factor kappa B role in inflammation associated gastrointestinal malignancies
Gambhir, S., Vyas, D., Hollis, M. V., Aekka, A., & Vyas, A. K. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i11.3174 · Cited by 117
Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy
Walters, J. R. F. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2014.32 · Cited by 112
Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review
Song, J., Li, Y., Bowlus, C. L., Yang, G., Leung, P. S. C., & Gershwin, M. E. (2019) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-019-08764-7 · Cited by 112
Counter-Regulatory Role of Bile Acid Activated Receptors in Immunity and Inflammation
Fiorucci, S., Cipriani, S., Mencarelli, A., Renga, B., Distrutti, E., & Baldelli, F. (2010) · Current Molecular Medicine · doi:10.2174/1566524011009060579 · Cited by 110
Geier, A., Dietrich, C. G., Voigt, S., Ananthanarayanan, M., Lammert, F., Schmitz, A., Trauner, M., Wasmuth, H. E., Boraschi, D., Balasubramaniyan, N., et al. (2005) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00307.2004 · Cited by 109
Self-citationRole of TGR5 (GPBAR1) in Liver Disease
Häussinger, D., & Keitel, V. (2018) · Seminars in Liver Disease · doi:10.1055/s-0038-1669940 · Cited by 106
Renga, B., Mencarelli, A., Cipriani, S., D'Amore, C., Carino, A., Bruno, A., Francisci, D., Zampella, A., Distrutti, E., & Fiorucci, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054472 · Cited by 103
Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15
Zhou, M., Luo, J., Chen, M., Yang, H., Learned, R. M., DePaoli, A. M., Tian, H., & Ling, L. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.027 · Cited by 102
Chen, W., & Chiang, J. Y. L. (2003) · Gene · doi:10.1016/s0378-1119(03)00631-0 · Cited by 101
Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects
Legry, V., Francque, S., Haas, J. T., Verrijken, A., Caron, S., Chávez-Talavera, O., Vallez, E., Vonghia, L., Dirinck, E., Verhaegen, A., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01397 · Cited by 101
Lax, S., Schauer, G., Prein, K., Kapitan, M., Silbert, D., Berghold, A., Berger, A., & Trauner, M. (2012) · International Journal of Cancer · doi:10.1002/ijc.26293 · Cited by 100
Self-citationBile acids: From digestion to cancers
Baptissart, M., Vega, A., Maqdasy, S., Caira, F., Baron, S., Lobaccaro, J.-M. A., & Volle, D. H. (2013) · Biochimie · doi:10.1016/j.biochi.2012.06.022 · Cited by 97
Mayo, M. J., Pockros, P. J., Jones, D., Bowlus, C. L., Levy, C., Patanwala, I., Bacon, B., Luketic, V., Vuppalanchi, R., Medendorp, S., et al. (2019) · Hepatology Communications · doi:10.1002/hep4.1305 · Cited by 97
Karpen, S. J., Kelly, D. A., Mack, C. L., & Stein, P. (2020) · Hepatology International · doi:10.1007/s12072-020-10070-w · Cited by 97
Al-Dury, S., & Marschall, H.-U. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00931 · Cited by 95
Singh, S., Khanna, S., Pardi, D. S., Loftus, E. V., & Talwalkar, J. A. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e318286fa61 · Cited by 94
Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver
Cicione, C., Degirolamo, C., & Moschetta, A. (2012) · Hepatology · doi:10.1002/hep.25929 · Cited by 94
Kim (2010) · International Journal of Oncology · doi:10.3892/ijo_00000573 · Cited by 93
Impact of bile acids on the growth of human cholangiocarcinoma via FXR
Dai, J., Wang, H., Shi, Y. H., Dong, Y., Zhang, Y., & Wang, J. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-41 · Cited by 93
Chen, L., van den Munckhof, I. C. L., Schraa, K., ter Horst, R., Koehorst, M., van Faassen, M., van der Ley, C., Doestzada, M., Zhernakova, D. V., Kurilshikov, A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108212 · Cited by 91
The Commensal Microbe V eillonella as a Marker for Response to an FGF19 Analog in NASH
Loomba, R., Ling, L., Dinh, D. M., DePaoli, A. M., Lieu, H. D., Harrison, S. A., & Sanyal, A. J. (2021) · Hepatology · doi:10.1002/hep.31523 · Cited by 88
Short-Term Regulation of Canalicular Transport
HÄUSSINGER, D., SCHMITT, M., WEIERGRÄBER, O., & KUBITZ, R. (2000) · Seminars in Liver Disease · doi:10.1055/s-2000-9386 · Cited by 88
Pizarro, M., Balasubramaniyan, N., Solís, N., Solar, A., Duarte, I., Miquel, J. F., Suchy, F. J., Trauner, M., Accatino, L., Ananthanarayanan, M., et al. (2004) · Gut · doi:10.1136/gut.2003.037689 · Cited by 87
Self-citationGuan, B., Li, H., Yang, Z., Hoque, A. M., & Xu, X. (2012) · Cancer · doi:10.1002/cncr.27910 · Cited by 86
Splenic dendritic cell involvement in FXR-mediated amelioration of DSS colitis
Massafra, V., Ijssennagger, N., Plantinga, M., Milona, A., Pittol, J. M. R., Boes, M. L., & van Mil, S. W. C. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.11.001 · Cited by 85
Ducastel, S., Touche, V., Trabelsi, M.-S., Boulinguiez, A., Butruille, L., Nawrot, M., Peschard, S., Chávez-Talavera, O., Dorchies, E., Vallez, E., et al. (2020) · Scientific Reports · doi:10.1038/s41598-019-56743-x · Cited by 84
Lindström, L., Boberg, K. M., Wikman, O., Friis‐Liby, I., Hultcrantz, R., Prytz, H., Sandberg‐Gertzén, H., Sangfelt, P., Rydning, A., Folvik, G., et al. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04966.x · Cited by 84
Bile acid metabolites control Th17 and Treg cell differentiation
Hang, S., Paik, D., Devlin, A. S., Jamma, T., Lu, J., Ha, S., Nelson, B. N., Kelly, S. P., Wu, L., Zheng, Y., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/465344 · Cited by 84
IL-17A Synergistically Enhances Bile Acid–Induced Inflammation during Obstructive Cholestasis
O'Brien, K. M., Allen, K. M., Rockwell, C. E., Towery, K., Luyendyk, J. P., & Copple, B. L. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.07.019 · Cited by 82
Bile acid receptors and nonalcoholic fatty liver disease
Yuan, L. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i28.2811 · Cited by 82
Cocarcinogenic Effects of Intrahepatic Bile Acid Accumulation in Cholangiocarcinoma Development
Lozano, E., Sanchez-Vicente, L., Monte, M. J., Herraez, E., Briz, O., Banales, J. M., Marin, J. J. G., & Macias, R. I. R. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0503 · Cited by 81
Transient impairment of the adaptive response to fasting in FXR‐deficient mice
Cariou, B., van Harmelen, K., Duran-Sandoval, D., van Dijk, T., Grefhorst, A., Bouchaert, E., Fruchart, J.-C., Gonzalez, F. J., Kuipers, F., & Staels, B. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.06.033 · Cited by 81
Induction of short heterodimer partner 1 precedes downregulation of Ntcp in bile duct-ligated mice
Zollner, G., Fickert, P., Silbert, D., Fuchsbichler, A., Stumptner, C., Zatloukal, K., Denk, H., & Trauner, M. (2002) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00215.2001 · Cited by 79
Self-citationRinella, M. E., Trotter, J. F., Abdelmalek, M. F., Paredes, A. H., Connelly, M. A., Jaros, M. J., Ling, L., Rossi, S. J., DePaoli, A. M., & Harrison, S. A. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.11.032 · Cited by 79
The PXR is a drug target for chronic inflammatory liver disease
Wallace, K., Cowie, D. E., Konstantinou, D. K., Hill, S. J., Tjelle, T. E., Axon, A., Koruth, M., White, S. A., Carlsen, H., Mann, D. A., et al. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.04.012 · Cited by 77
Mroz, M. S., Keating, N., Ward, J. B., Sarker, R., Amu, S., Aviello, G., Donowitz, M., Fallon, P. G., & Keely, S. J. (2014) · Gut · doi:10.1136/gutjnl-2013-305088 · Cited by 77
Hackstein, C.-P., Assmus, L. M., Welz, M., Klein, S., Schwandt, T., Schultze, J., Förster, I., Gondorf, F., Beyer, M., Kroy, D., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-311224 · Cited by 77
Nguyen, T. T., Lian, S., Ung, T. T., Xia, Y., Han, J., & Jung, Y. D. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25955 · Cited by 76
Byun, S., Kim, D.-H., Ryerson, D., Kim, Y.-C., Sun, H., Kong, B., Yau, P., Guo, G., Xu, H. E., Kemper, B., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04697-5 · Cited by 75
Peng, S., Huo, X., Rezaei, D., Zhang, Q., Zhang, X., Yu, C., Asanuma, K., Cheng, E., Pham, T. H., Wang, D. H., et al. (2014) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00085.2014 · Cited by 73
Dendritic cells and liver fibrosis
Rahman, A. H., & Aloman, C. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.01.005 · Cited by 73
Canet, M. J., Merrell, M. D., Hardwick, R. N., Bataille, A. M., Campion, S. N., Ferreira, D. W., Xanthakos, S. A., Manautou, J. E., A‐Kader, H. H., Erickson, R. P., et al. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.062703 · Cited by 73
Allen, K., Kim, N. D., Moon, J.-O., & Copple, B. L. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.11.013 · Cited by 70
Han, S. I., Studer, E., Gupta, S., Fang, Y., Qiao, L., Li, W., Grant, S., Hylemon, P. B., & Dent, P. (2004) · Hepatology · doi:10.1002/hep.20043 · Cited by 68
Baek, M. K., Park, J. S., Park, J., Kim, M. H., Kim, H. D., Bae, W. K., Chung, I. J., Shin, B. A., & Jung, Y. D. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.08.030 · Cited by 66
Bile acid analogues are activators of pyrin inflammasome
Alimov, I., Menon, S., Cochran, N., Maher, R., Wang, Q., Alford, J., Concannon, J. B., Yang, Z., Harrington, E., Llamas, L., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005103 · Cited by 64
Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
Heinzle, C. F., Erdem, Z., Paur, J., Grasl‐Kraupp, B., Holzmann, K., Grusch, M., Berger, W., & Marian, B. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990594 · Cited by 64
GLP-1: A Mediator of the Beneficial Metabolic Effects of Bariatric Surgery?
Manning, S., Pucci, A., & Batterham, R. L. (2015) · Physiology · doi:10.1152/physiol.00027.2014 · Cited by 63
NASH-related increases in plasma bile acid levels depend on insulin resistance
Grzych, G., Chávez-Talavera, O., Descat, A., Thuillier, D., Verrijken, A., Kouach, M., Legry, V., Verkindt, H., Raverdy, V., Legendre, B., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2020.100222 · Cited by 63
Cao, H., Chen, Z., Wang, K., Ning, M., Zou, Q., Feng, Y., Ye, Y., Leng, Y., & Shen, J. (2016) · Scientific Reports · doi:10.1038/srep28676 · Cited by 62
Lasalle, M., Hoguet, V., Hennuyer, N., Leroux, F., Piveteau, C., Belloy, L., Lestavel, S., Vallez, E., Dorchies, E., Duplan, I., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01873 · Cited by 61
Hansen, J. D., Kumar, S. R., Lo, W., Poulsen, D., Halai, U., & Tater, K. C. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-2772-0 · Cited by 60
TGR5: Pathogenetic Role and/or Therapeutic Target in Fibrosing Cholangitis?
Keitel, V., Reich, M., & Häussinger, D. (2014) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-014-8443-x · Cited by 59
Role of early growth response 1 in liver metabolism and liver cancer
Magee, N. S., & Zhang, Y. (2017) · Hepatoma Research · doi:10.20517/2394-5079.2017.36 · Cited by 58
Peng, Z., Raufman, J., & Xie, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048461 · Cited by 57
Bile Acid‐Induced Toxicity in Hepa RG Cells Recapitulates the Response in Primary Human Hepatocytes
Woolbright, B. L., McGill, M. R., Yan, H., & Jaeschke, H. (2015) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12449 · Cited by 54
Attinkara, R., Mwinyi, J., Truninger, K., Regula, J., Gaj, P., Rogler, G., Kullak-Ublick, G. A., Eloranta, J. J., & The Swiss IBD Cohort Study Group (2012) · BMC Research Notes · doi:10.1186/1756-0500-5-461 · Cited by 54
Lucas, K. J., Lopez, P., Lawitz, E., Sheikh, A. M., Aizenberg, D., Hsia, S. H., Goh, B. B. G., Vierling, J. M., Frias, J., White, J., et al. (2020) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.12.129 · Cited by 51
FXR mediates T cell-intrinsic responses to reduced feeding during infection
Campbell, C., Marchildon, F., Michaels, A. J., Takemoto, N., van der Veeken, J., Schizas, M., Pritykin, Y., Leslie, C. S., Intlekofer, A. M., Cohen, P., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2020619117 · Cited by 50
Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders
Trauner, M., Halilbasic, E., Claudel, T., Steinacher, D., Fuchs, C., Moustafa, T., Pollheimer, M., Krones, E., Kienbacher, C., Traussnigg, S., et al. (2015) · Digestive Diseases · doi:10.1159/000371904 · Cited by 49
Self-citationLicata, L. A., Nguyen, C. T., Burga, R. A., Falanga, V., Espat, N. J., Ayala, A., Thorn, M., Junghans, R. P., & Katz, S. C. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0313137 · Cited by 49
Divergent homeobox gene Hex regulates promoter of the Na+-dependent bile acid cotransporter
Denson, L. A., Karpen, S. J., Bogue, C. W., & Jacobs, H. C. (2000) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2000.279.2.g347 · Cited by 46
Novel bile acid therapeutics for the treatment of chronic liver diseases
Hegade, V. S., Speight, R. A., Etherington, R. E., & Jones, D. E. J. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16630712 · Cited by 44
Lozano, E., Monte, M. J., Briz, Ó., Hernández‐Hernández, Á., Bañales, J. M., Marı́n, J. J. G., & Macı́as, R. I. R. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.022 · Cited by 43
FXR activation inhibits inflammation and preserves the intestinal barrier in IBD
Wildenberg, M. E., & van den Brink, G. R. (2011) · Gut · doi:10.1136/gut.2010.233304 · Cited by 43
Park, M. J., Kong, H. J., Kim, H. Y., Kim, H. H., Kim, J. H., & Cheong, J. H. (2007) · Biochemical Journal · doi:10.1042/bj20061549 · Cited by 42
Effects of LPS on transport of indocyanine green and alanine uptake in perfused rat liver
Lund, M. A., Kang, L., Tygstrup, N., Wolkoff, A. W., & Ott, P. (1999) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1999.277.1.g91 · Cited by 41
Wagner, M., Zollner, G., & Trauner, M. (2008) · Hepatology · doi:10.1002/hep.22668 · Cited by 40
Self-citationDifferential expression of influx and efflux transport proteins in human antigen presenting cells
Skazik, C., Heise, R., Bostanci, Ö., Paul, N. E., Denecke, B., Joussen, S., Kiehl, K., Merk, H. F., Zwadlo‐Klarwasser, G., & Baron, J. M. (2008) · Experimental Dermatology · doi:10.1111/j.1600-0625.2008.00745.x · Cited by 40
Voltage-dependent outward K+current in intermediate cell of stria vascularis of gerbil cochlea
Takeuchi, S., & Ando, M. (1999) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1999.277.1.c91 · Cited by 40
Halilbasic, E., Fuchs, C., Traussnigg, S., & Trauner, M. (2016) · Digestive Diseases · doi:10.1159/000445268 · Cited by 39
Self-citationOduyebo, I., Camilleri, M., Nelson, A. D., Khemani, D., Nord, S. L., Busciglio, I. A., Burton, D. D., Rhoten, D. L., Ryks, M. D., Carlson, P., et al. (2018) · The American Journal of Gastroenterology · doi:10.1038/s41395-018-0042-7 · Cited by 39
Acalovschi, M., Tirziu, S., Chiorean, E., Krawczyk, M. J., Grünhage, F., & Lammert, F. (2009) · Lipids · doi:10.1007/s11745-009-3300-z · Cited by 38
Contributing factors and outcomes of burn-associated cholestasis
de Tymowski, C., Dépret, F., Soussi, S., Moreno, N., Vauchel, T., Chaussard, M., Benyamina, M., Ferry, A., Cupaciu, A., Jully, M., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.05.009 · Cited by 36
Biliary Obstruction Selectively Expands and Activates Liver Myeloid Dendritic Cells
Bleier, J. I., Katz, S. C., Chaudhry, U. I., Pillarisetty, V. G., Kingham, T. P., Shah, A. B., Raab, J. R., & DeMatteo, R. P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.12.7189 · Cited by 35
Kühlkamp, T., Keitel, V., Helmer, A., Häussinger, D., & Kubitz, R. (2005) · Biological Chemistry · doi:10.1515/bc.2005.122 · Cited by 35
Early events in sepsis-associated cholestasis
Jansen, P. L. M., & Müller, M. M. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70147-2 · Cited by 35
Camilleri, M., Klee, E. W., Shin, A., Carlson, P., Li, Y., Grover, M., & Zinsmeister, A. R. (2014) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00294.2013 · Cited by 35
Smith, D. L. H., Keshavan, P., Avissar, U., Ahmed, K., & Zucker, S. D. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq050 · Cited by 32
Bile Acid Signaling: Mechanism for Bariatric Surgery, Cure for NASH?
Kohli, R., Myronovych, A., Tan, B. K., Salazar-Gonzalez, R.-M., Miles, L., Zhang, W., Oehrle, M., Sandoval, D. A., Ryan, K. K., Seeley, R. J., et al. (2015) · Digestive Diseases · doi:10.1159/000371699 · Cited by 29
Fibroinflammatory Liver Injuries as Preneoplastic Condition in Cholangiopathies
Cannito, S., Milani, C., Cappon, A., Parola, M., Strazzabosco, M., & Cadamuro, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123875 · Cited by 26
Sodium deoxycholate causes nitric oxide mediated DNA damage in oesophageal cells
Jolly, A. J., Wild, C. P., & Hardie, L. J. (2009) · Free Radical Research · doi:10.1080/10715760802684211 · Cited by 25
van Schaik, F. D. M., Gadaleta, R. M., Schaap, F. G., van Mil, S. W. C., Siersema, P. D., Oldenburg, B., & van Erpecum, K. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049706 · Cited by 25
Bile acids in nonalcoholic steatohepatitis: Pathophysiological driving force or innocent bystanders?
Jahn, D., & Geier, A. (2017) · Hepatology · doi:10.1002/hep.29543 · Cited by 24
Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis
Brouwer, K. L. R., Barritt, A. S., Xie, G., Ferslew, B. C., Jia, W. P., Johnston, C., Stewart, P. W., & Su, M. (2020) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/v9a5-p335 · Cited by 24
Arvind, P., Papavassiliou, E. D., Tsioulias, G. J., Duceman, B. W., Lovelace, C. I. P., Wang, G., Staiano‐Coico, L., & Rigas, B. (1994) · Molecular Immunology · doi:10.1016/0161-5890(94)90168-6 · Cited by 23
Abdel-Latif, M., Inoue, H., & Reynolds, J. V. (2015) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000198 · Cited by 19
Chiang, J. Y. L. (2015) · Hepatology · doi:10.1002/hep.27616 · Cited by 17
d'Aldebert, E., Mve, M.-J. B. B., Mergey, M., Wendum, D., Coilly, A., Fouassier, L., Corpechot, C., Poupon, R. Y., Housset, C., & Chignard, N. (2009) · Springer eBooks · doi:10.1007/978-1-4020-9644-0_13 · Cited by 17
A variant of FGF19 for treatment of disorders of cholestasis and bile acid metabolism.
Walters, J. R. F., & Appleby, R. (2015) · PubMed · doi:10.3978/j.issn.2305-5839.2015.03.38 · Cited by 13
Mangia, A., Milligan, S., Khalili, M., FAGIUOLI, S., Shafran, S. D., Carrat, F., Ouzan, D., Papatheodoridis, G., Ramji, A. S., Borgia, S. M., et al. (2019) · Journal of Hepatology · doi:10.1016/s0618-8278(19)30003-9 · Cited by 13
Bile acids mediate signaling between microbiome and the immune system
Liston, A., & Whyte, C. E. (2020) · Immunology and Cell Biology · doi:10.1111/imcb.12332 · Cited by 13
Marschall, H.-U., Wagner, M., Zollner, G., Fickert, P., Silbert, D., Gustafsson, U., Sahlin, S., & Trauner, M. (2012) · Digestion · doi:10.1159/000341420 · Cited by 7
Self-citationGadaleta, R., Oldenburg, B., Willemsen, E., Spit, M., Murzilli, S., Salvatore, L., Klomp, L. W. J., Siersema, P. D., Erpecum, K. V., & van Mil, S. (2011) · UCL Discovery (University College London) · Cited by 7
Cholangitis Lenta: What Hepatologists Need to Know
Booth, A. L., Merwat, S. N., Merwat, S. K., & Stevenson, H. L. (2020) · Clinical Liver Disease · doi:10.1002/cld.907 · Cited by 6
Cited by
Bile acids and the gut microbiota: metabolic interactions and impacts on disease
Collins, S. L., Stine, J. G., Bisanz, J. E., Okafor, C. D., & Patterson, A. D. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00805-x · Cited by 1,214
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01743-1 · Cited by 1,193
Gut-liver axis: Pathophysiological concepts and clinical implications
Tilg, H., Adolph, T. E., & Trauner, M. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.09.017 · Cited by 843
Self-citationThe gut–liver axis and gut microbiota in health and liver disease
Hsu, C. L., & Schnabl, B. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00904-3 · Cited by 737
Gut–liver axis: barriers and functional circuits
Pabst, O., Hornef, M. W., Schaap, F. G., Cerovic, V., Clavel, T., & Bruns, T. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00771-6 · Cited by 436
Metadata
- Authors
- Fuchs, C. D., & Trauner, M.
- Affiliations
- Medical University of Vienna (AT)
- Corresponding author
- Trauner, Michael
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2022-02-14
- Volume
- 19
- Issue
- 7
- Pages
- 432-450
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- OpenAlex
- W4212954224
- Cited by
- 490
- References
- 300
- Citations by year
- 2026: 134 · 2025: 145 · 2024: 111 · 2023: 77 · 2022: 23
- FWCI
- 10.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Gastroenterology & Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- bile acids, bile acid receptors, nuclear receptors, G protein-coupled receptors, bile acid homeostasis, bile acid transport, cholestasis, non-alcoholic fatty liver disease, hepatocellular carcinoma, cholangiocarcinoma, irritable bowel syndrome, inflammatory bowel disease, colorectal cancer, esophageal cancer
- MeSH terms
- Bile Acids and Salts, Cholestasis, Homeostasis, Humans, Liver, Receptors, G-Protein-Coupled, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.